Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The page displays the clinical trial record, including its terminated status, study design, eligibility criteria, outcomes, locations, and record dates, instead of a 403 error response.
    Difference
    48%
    Check dated 2026-11-07T12:19:17.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of study details.
    Difference
    0.2%
    Check dated 2026-10-31T13:10:08.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    A banner appears announcing NIH website transition updates and FAQs, with a notice that federal agencies are using “Super Intelligence” instead of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-24T13:44:06.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-17T14:31:48.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-10T14:38:51.000Z thumbnail image
  7. Check
    51 days ago
    Change Detected
    Summary
    The study details page now displays a 403 Forbidden error in place of the content. This indicates an access restriction and prevents viewing the study record and page navigation as before.
    Difference
    0.5%
    Check dated 2026-09-26T16:28:27.000Z thumbnail image

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.